GlassScriptPhysician profile
Virginia E Kimonis
NPI 1912964925
$79,282.16
in general payments reported to CMS, 2019-2025
11 companies · $15K in 2025
The $15K reported for 2025 was more than what 89% of Clinical Genetics (M.D.) providers received nationally (typical 2025 total: $255).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $11K · 2021: $3,248 · 2022: $14K · 2023: $7,941 · 2024: $14K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,596 · Honoraria: $4,025 · Travel and Lodging: $3,827 · Food and Beverage: $1,348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,955.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,596.00 |
| Honoraria | $4,025.00 |
| Travel and Lodging | $3,826.85 |
| Food and Beverage | $1,347.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $69,090.35 | 2019-2025 | |
| Chiesi USA, INC. | $8,806.45 | 2020-2025 | Elfabrio |
| Amicus Therapeutics, INC. | $1,192.00 | 2020 | |
| Ptc Therapeutics, INC. | $78.96 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.32 | 2023-2024 | |
| Soleno Therapeutics, INC. | $36.65 | 2025 | Vykat Xr |
| Argenx US, INC. | $22.94 | 2024 | Vyvgart |
| Travere Therapeutics, INC. | $2.49 | 2019-2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Virginia Kimonis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.